572 related articles for article (PubMed ID: 29945562)
21. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Pelzer U; Blanc JF; Melisi D; Cubillo A; Von Hoff DD; Wang-Gillam A; Chen LT; Siveke JT; Wan Y; Solem CT; Botteman MF; Yang Y; de Jong FA; Hubner RA
Br J Cancer; 2017 May; 116(10):1247-1253. PubMed ID: 28350787
[TBL] [Abstract][Full Text] [Related]
22. Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study.
Tezuka S; Ueno M; Kobayashi S; Hamaguchi T; Yamachika Y; Oishi R; Nagashima S; Fukushima T; Morimoto M; Shin M
Pancreatology; 2022 Sep; 22(6):789-796. PubMed ID: 35705458
[TBL] [Abstract][Full Text] [Related]
23. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial.
Macarulla Mercadé T; Chen LT; Li CP; Siveke JT; Cunningham D; Bodoky G; Blanc JF; Lee KH; Dean A; Belanger B; Wang-Gillam A
Pancreas; 2020 Jan; 49(1):62-75. PubMed ID: 31856081
[TBL] [Abstract][Full Text] [Related]
24. Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer.
Takada R; Ikezawa K; Yamai T; Watsuji K; Seiki Y; Kawamoto Y; Hirao T; Higashi S; Urabe M; Kai Y; Nakabori T; Uehara H; Kotani M; Yagi T; Kimura M; Nozaki K; Takagi M; Ohkawa K
BMC Cancer; 2023 Jul; 23(1):711. PubMed ID: 37518012
[TBL] [Abstract][Full Text] [Related]
25. A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium.
Verbruggen L; Verheggen L; Vanhoutte G; Loly C; Lybaert W; Borbath I; Vergauwe P; Hendrickx K; Debeuckelaere C; de Haar-Holleman A; Van Laethem JL; Peeters M
Ther Adv Med Oncol; 2023; 15():17588359231181500. PubMed ID: 37600936
[TBL] [Abstract][Full Text] [Related]
26. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy.
Bang K; Cheon J; Jeong JH; Im HS; Kim KP; Ryoo BY; Yoo C
Ther Adv Med Oncol; 2021; 13():17588359211003053. PubMed ID: 33796153
[TBL] [Abstract][Full Text] [Related]
28. Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience.
Tossey JC; Reardon J; VanDeusen JB; Noonan AM; Porter K; Arango MJ
Med Oncol; 2019 Sep; 36(10):87. PubMed ID: 31494781
[TBL] [Abstract][Full Text] [Related]
29. Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315).
Ettrich TJ; Modest DP; Sinn M; Striefler JK; Opitz B; Goetze T; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Jacobasch L; Waldschmidt D; Niedermeier M; Sohm M; Berger AW; Manzini G; Fehrenbach U; Auer TA; Hosse C; Vogele D; Sookthai D; Schaaf M; Muche R; Hinke A; Seufferlein T; Perkhofer L
J Clin Oncol; 2024 Jun; ():JCO2301566. PubMed ID: 38843469
[TBL] [Abstract][Full Text] [Related]
30. The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort.
Su YY; Chiang NJ; Tsai HJ; Yen CJ; Shan YS; Chen LT
Sci Rep; 2020 May; 10(1):7420. PubMed ID: 32366911
[TBL] [Abstract][Full Text] [Related]
31. 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice.
Yamai T; Ikezawa K; Kawamoto Y; Hirao T; Higashi S; Daiku K; Maeda S; Abe Y; Urabe M; Kai Y; Takada R; Nakabori T; Uehara H; Ohkawa K
Curr Oncol; 2022 Apr; 29(4):2644-2649. PubMed ID: 35448190
[TBL] [Abstract][Full Text] [Related]
32. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States.
Barzi A; Miksad R; Surinach A; Corvino FA; Wang S; Torres AZ; Mamlouk K; Pulgar S; Valderrama A; Bekaii-Saab T; Ahn D
Pancreas; 2020 Feb; 49(2):193-200. PubMed ID: 32011529
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of the combination of nano-liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma: post-approval clinic experience.
Kasi A; McGinnis T; Naik G; Handa S; Williams G; Paluri R
J Gastrointest Oncol; 2021 Apr; 12(2):464-473. PubMed ID: 34012640
[TBL] [Abstract][Full Text] [Related]
34. A Retrospective Study Investigating the Safety and Efficacy of Nanoliposomal Irinotecan in Elderly Patients with Unresectable Pancreatic Cancer.
Ikoma T; Matsumoto T; Boku S; Yasuda T; Masuda M; Ito T; Nakamaru K; Yamaki S; Nakayama S; Hashimoto D; Yamamoto T; Shibata N; Ikeura T; Naganuma M; Satoi S; Kurata T
J Clin Med; 2023 May; 12(10):. PubMed ID: 37240585
[TBL] [Abstract][Full Text] [Related]
35. Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials.
Merz V; Messina C; Zecchetto C; Quinzii A; Frisinghelli M; Trentin C; Salati M; Caffo O; Melisi D
Clin Oncol (R Coll Radiol); 2024 Feb; 36(2):87-97. PubMed ID: 38129199
[TBL] [Abstract][Full Text] [Related]
36. A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy.
Grierson PM; Suresh R; Tan B; Pedersen KS; Amin M; Park H; Trikalinos NA; Liu J; Boice N; Brown A; Bansod S; Wang-Gillam A; Lim KH
Clin Cancer Res; 2023 Dec; 29(23):4733-4739. PubMed ID: 37801295
[TBL] [Abstract][Full Text] [Related]
37. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1.
Chen LT; Macarulla T; Blanc JF; Mirakhur B; de Jong FA; Belanger B; Bekaii-Saab T; Siveke JT
Pancreatology; 2021 Jan; 21(1):192-199. PubMed ID: 33214082
[TBL] [Abstract][Full Text] [Related]
38. A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid.
Kieler M; Unseld M; Bianconi D; Scheithauer W; Prager GW
Ther Adv Med Oncol; 2019; 11():1758835919853196. PubMed ID: 31360237
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
Hong E; Park S; Ooshima A; Hong CP; Park J; Heo JS; Lee S; An H; Kang JM; Park SH; Park JO; Kim SJ
Sci Rep; 2020 Feb; 10(1):2935. PubMed ID: 32076068
[TBL] [Abstract][Full Text] [Related]
40. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).
Park HS; Kang B; Chon HJ; Im HS; Lee CK; Kim I; Kang MJ; Hwang JE; Bae WK; Cheon J; Park JO; Hong JY; Kang JH; Kim JH; Lim SH; Kim JW; Kim JW; Yoo C; Choi HJ
ESMO Open; 2021 Apr; 6(2):100049. PubMed ID: 33578192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]